Acne Among Japanese Patients with Atopic Dermatitis Receiving Upadacitinib in the Phase 3 Rising Up Study

• Main Authors: Nobukazu Hayashi (Author), Masanori Ikeda (Author), John Liu (Author), Eliza Raymundo (Author), Yingyi Liu (Author), Takuya Sasaki (Author), Kenshi Yamasaki (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2023-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction Upadacitinib, an oral selective Janus kinase (JAK) inhibitor, is used to treat moderate-to-severe atopic dermatitis (AD). Acne is the most common treatment-emergent adverse event in patients with AD treated with upadacitinib. In this post hoc analysis, we describe the acne even...